Navigation Links
Imago BioSciences Announces Preclinical Data on LSD1 Inhibitor at Annual Meeting of the American Society of Hematology (ASH)

SAN FRANCISCO, Dec. 7, 2015 /PRNewswire/ -- Imago BioSciences, Inc., a biotech company developing innovative therapeutics for myeloid diseases, today announced a presentation at the 57th ASH Annual Meeting this week in Orlando, Florida.  The oral presentation titled "Lysine-Specific Histone Demethylase, LSDI (KDM1A) As a Novel Therapeutic Target in Myeloproliferative Neoplasms," outlines the beneficial effects including a reduction in mutant cells and reversal of fibrosis by inhibiting LSD1 in a well-established mouse model of myelofibrosis.

"We are delighted to be a part of the team generating these important data.  These are the first data to implicate LSD1 in the pathogenesis of a myeloproliferative neoplasm disease such as myelofibrosis," said Hugh Young Rienhoff, Jr. M.D., CEO at Imago BioSciences and a co-author of the study. "We are enthusiastic about the potential clinical benefit myelofibrosis patients might enjoy given the unmet need for a medicine that alters the natural history of this vicious disease.  The biology underlying these experiments directly advances our ongoing research and development of LSD1 inhibitors for the treatment of myeloid diseases."

Recent studies have shown that the lysine-specific demethylase LSD1, participates in the balance between hematopoietic cell proliferation and differentiation in hematopoietic stem and progenitor cells.  LSD1 appears essential for maintaining malignant myeloid stem and progenitor cells in the undifferentiated and self-renewing state.   

In the experiment presented, mice with myelofibrosis secondary to the activated thrombopoietin receptor (MplW515L) were treated with an oral Imago LSD1 inhibitor.  Treated mice showed reduced splenomegaly, decreased platelet counts, a marked reduction in key cytokines, a resolution of bone marrow fibrosis and a reduction of mutant allele burden over the course of the 4 week treatment period.  These and other unpublished data support LSD1 as a valid drug target in myelofibrosis.  The Imago LSD1 inhibitor will enter the clinic next year.

About Imago BioSciences

Imago BioSciences is a San Francisco-based clinical development company dedicated to translating state-of-the art science into novel medicines for treating diseases that currently pose great challenges to patients, their families and their physicians.  The company leverages the skills and extensive experience of its team and the financial commitment of its investors to focus on a small family of orphan diseases.  Imago BioSciences translates unique insights into high impact transformative therapies that alter the natural history of disease allowing patients to live longer, disease-free lives.  More information is available at

Investor and Media Contact:


SOURCE Imago BioSciences
Copyright©2015 PR Newswire.
All rights reserved

Related biology technology :

1. New Hudsonville-Based Biomedical Startup, Imago Prints, Uses Patient-Specific Ultrasound Data to Produce One-of-a-Kind 3D Printed Renderings of Infants During Pregnancy
2. Perrigo Announces the Out-Licensing of Preclinical Assets to Imago Pharmaceuticals
3. New Applications of Pressure BioSciences PCT Platform Prominently Featured at Scientific Conference on Technologies for Protein Research
4. Northstar Biosciences Launches All Natural Skincare Solutions
5. Further Advancements Made in the Development of an Improved Method For Rape Kit Testing Using Pressure BioSciences Patented Pressure Cycling Technology (PCT)
6. Sangamo BioSciences Announces Presentation At Regen Med Investor Day
7. Sangamo BioSciences Announces Presentation At The Needham Healthcare Conference
8. Centrillion Biosciences Announces Next-Gen Sequencing Innovation Grant Program
9. Quanta BioSciences qRT-PCR technology recommended in newly published CDC protocol for detection of H7N9 Avian Influenza
10. Regado Biosciences, Inc. Files Registration Statement for Proposed Initial Public Offering
11. Provitro Biosciences Awarded First-Ever U.S. Patent For Large-Scale Production Of Bamboo Plants
Post Your Comments:
(Date:10/11/2017)... , ... October 11, 2017 , ... ... the implantation and pregnancy rates in frozen and fresh in vitro fertilization ... progesterone and maternal age to IVF success. , After comparing the results from ...
(Date:10/10/2017)... ... October 10, 2017 , ... Dr. Bob Harman, founder and CEO of ... Rotary Club. The event entitled “Stem Cells and Their Regenerative Powers,” ... Dr. Harman, DVM, MPVM was joined by two human doctors: Peter B. Hanson, ...
(Date:10/9/2017)... DIEGO , Oct. 9, 2017  BioTech ... biological mechanism by which its ProCell stem cell ... critical limb ischemia.  The Company, demonstrated that treatment ... amount of limbs saved as compared to standard ... the molecule HGF resulted in reduction of therapeutic ...
(Date:10/7/2017)... , ... October 06, 2017 ... ... experience providing advanced instruments and applications consulting for microscopy and surface analysis, ... in application consulting, Nanoscience Analytical offers a broad range of contract analysis ...
Breaking Biology Technology:
(Date:6/30/2017)... 2017 Today, American Trucking Associations announced ... face and eye tracking software, became the newest ... "Artificial intelligence and advanced sensing ... a driver,s attentiveness levels while on the road.  ... detect fatigue and prevent potential accidents, which could ...
(Date:5/16/2017)... 16, 2017   Bridge Patient Portal , ... MD EMR Systems , an electronic medical ... GE, have established a partnership to build an ... the GE Centricity™ products, including Centricity Practice Solution ... These new integrations will allow healthcare delivery ...
(Date:4/17/2017)... 17, 2017 NXT-ID, Inc. (NASDAQ: NXTD ... filing of its 2016 Annual Report on Form 10-K on Thursday ... ... available in the Investor Relations section of the Company,s website at ... website at . 2016 Year Highlights: ...
Breaking Biology News(10 mins):